Authors:
Burger, AM
Mengs, U
Schuler, JB
Fiebig, HH
Citation: Am. Burger et al., Anticancer activity of an aqueous mistletoe extract (AME) in syngeneic murine tumor models, ANTICANC R, 21(3B), 2001, pp. 1965-1968
Authors:
Lerchen, HG
Baumgarten, J
von dem Bruch, K
Lehmann, TE
Sperzel, M
Kempka, G
Fiebig, HH
Citation: Hg. Lerchen et al., Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents, J MED CHEM, 44(24), 2001, pp. 4186-4195
Authors:
Easmon, J
Purstinger, G
Heinisch, G
Roth, T
Fiebig, HH
Holzer, W
Jager, W
Jenny, M
Hofmann, J
Citation: J. Easmon et al., Synthesis, cytotoxicity, and antitumor activity of copper(II) and iron(II)complexes of N-4-azabicyclo[3.2.2]nonane thiosemicarbazones derived from acyl diazines, J MED CHEM, 44(13), 2001, pp. 2164-2171
Authors:
Easmon, J
Puerstinger, G
Roth, T
Fiebig, HH
Jenny, M
Jaeger, W
Heinisch, G
Hofmann, J
Citation: J. Easmon et al., 2-benzoxazolyl and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine: A novel class of antitumor agents, INT J CANC, 94(1), 2001, pp. 89-96
Authors:
Burger, AM
Hartung, G
Stehle, G
Sinn, H
Fiebig, HH
Citation: Am. Burger et al., Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo, INT J CANC, 92(5), 2001, pp. 718-724
Authors:
Phillips, RM
Burger, AM
Fiebig, HH
Double, JA
Citation: Rm. Phillips et al., Genotyping of NAD(P)H : quinone oxidoreductase (NQO1) in a panel of human tumor xenografts: relationship between genotype status, NQO1 activity and the response of xenografts to Mitomycin C chemotherapy in vivo, BIOCH PHARM, 62(10), 2001, pp. 1371-1377
Authors:
Burger, AM
Mengs, U
Schuler, JB
Fiebig, HH
Citation: Am. Burger et al., Antiproliferative activity of an aqueous mistletoe extract in human tumor cell lines and xenografts in vitro, ARZNEI-FOR, 51(9), 2001, pp. 748-757
Authors:
Manzotti, C
Pratesi, G
Menta, E
Di Domenico, R
Cavalletti, E
Fiebig, HH
Kelland, LR
Farrell, N
Polizzi, D
Supino, R
Pezzoni, G
Zunino, F
Citation: C. Manzotti et al., BBR 3464: A novel triplatinum complex, exhibiting a preclinical profile ofantitumor efficacy different from cisplatin, CLIN CANC R, 6(7), 2000, pp. 2626-2634
Authors:
Kratz, F
Roth, T
Fichiner, I
Schumacher, P
Fiebig, HH
Unger, C
Citation: F. Kratz et al., In vitro and in vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB-435 mammacarcinoma model, J DRUG TAR, 8(5), 2000, pp. 305-318
Citation: Hh. Fiebig et al., No evidence of tumor growth stimulation in human tumors in vitro followingtreatment with recombinant human growth hormone, ANTI-CANC D, 11(8), 2000, pp. 659-664
Authors:
Renneberg, B
Li, YM
Laatsch, H
Fiebig, HH
Citation: B. Renneberg et al., A short and efficient transformation of rhamnose into activated daunosamine, acosamine, ristosamine and epi-daunosamine derivatives, and synthesis ofan anthracycline antibiotic acosaminyl-epsilon-iso-rhodomycinone, CARBOHY RES, 329(4), 2000, pp. 861-872
Authors:
Phillips, RM
Burger, AM
Loadman, PM
Jarrett, CM
Swaine, DJ
Fiebig, HH
Citation: Rm. Phillips et al., Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: Implications for enzyme-directed bioreductive drug development, CANCER RES, 60(22), 2000, pp. 6384-6390
Authors:
Hartung, G
Stehle, G
Sinn, H
Wunder, A
Schrenk, HH
Heeger, S
Kranzle, M
Edler, L
Frei, E
Fiebig, HH
Heene, DL
Maier-Borst, W
Queisser, W
Citation: G. Hartung et al., Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients, CLIN CANC R, 5(4), 1999, pp. 753-759
Authors:
Rodrigues, PCA
Beyer, U
Schumacher, P
Roth, T
Fiebig, HH
Unger, C
Messori, L
Orioli, P
Paper, DH
Mulhaupt, R
Kratz, F
Citation: Pca. Rodrigues et al., Acid-sensitive polyethylene glycol conjugates of doxorubicin: Preparation,in vitro efficacy and intracellular distribution, BIO MED CH, 7(11), 1999, pp. 2517-2524
Authors:
Hill, BT
Fiebig, HH
Waud, WR
Poupon, MF
Colpaert, F
Kruczynski, A
Citation: Bt. Hill et al., Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts, EUR J CANC, 35(3), 1999, pp. 512-520
Authors:
Hendriks, HR
Fiebig, HH
Giavazzi, R
Langdon, SP
Jimeno, JM
Faircloth, GT
Citation: Hr. Hendriks et al., High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer, ANN ONCOL, 10(10), 1999, pp. 1233-1240
Authors:
Mross, K
Berdel, WE
Fiebig, HH
Velagapudi, R
von Broen, IM
Unger, C
Citation: K. Mross et al., Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer, ANN ONCOL, 9(12), 1998, pp. 1323-1330
Authors:
Rassmann, I
Thodtmann, R
Mross, M
Huttmann, A
Berdel, WE
Manegold, C
Fiebig, HH
Kaeser-Frohlich, A
Burk, K
Hanauske, AR
Citation: I. Rassmann et al., Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion, INV NEW DR, 16(4), 1998, pp. 319-324